Accenture stock hits 52-week low at $274.96

Accenture (ACN) recently hit a 52-week low of $274.96 amid broader market pressures, despite maintaining a "GOOD" financial health score and a healthy current ratio of 1.48; the company is restructuring operations into a new Reinvention Services unit led by Manish Sharma, effective September 2025. Concurrently, Accenture expanded its AI Refinery platform in Europe and invested in AI claims processor Reserv, while analysts at Morgan Stanley lowered their price target to $340 due to macroeconomic concerns, and Stifel maintained a Buy rating with a $355 target, anticipating the company will meet fiscal third-quarter targets.

Analysis

Accenture (NYSE:ACN) recently touched a 52-week low of $274.96, reflecting broader market conditions and a slight 1-year stock decline of -0.84%, despite maintaining a "GOOD" Financial Health score according to InvestingPro. The company exhibits strong fundamentals, evidenced by a healthy current ratio of 1.48 and moderate debt levels, supporting its $191.8 billion market capitalization. Notably, five analysts have recently revised earnings estimates upward. Strategically, Accenture is undergoing a significant operational restructuring, effective September 1, 2025, to create a new integrated business unit, Reinvention Services, led by Manish Sharma as the first Chief Services Officer, consolidating Strategy, Consulting, Song, Technology, and Operations. The company is also advancing its AI capabilities, expanding its AI Refinery platform in Europe with new features built on NVIDIA Enterprise AI to address data sovereignty, and has invested in Reserv, an AI-driven insurance claims processing firm. Analyst perspectives are mixed: Morgan Stanley lowered its price target to $340 from a previous level, maintaining an Equalweight rating due to macroeconomic concerns, yet anticipates Accenture may raise the lower end of its fiscal year 2025 growth guidance by 100 basis points. Conversely, Stifel reiterated a Buy rating and a $355 price target, expecting Accenture to meet its fiscal third-quarter targets. Analyst price targets for Accenture broadly range from $290 to $395.

Key Decisions for Investors

• Investors should evaluate the current 52-week low as a potential entry point, considering the company's strong fundamentals and 'GOOD' financial health score against prevailing macroeconomic headwinds.
• Monitor the progress of the significant operational restructuring into 'Reinvention Services' and the traction of AI initiatives, such as the AI Refinery platform expansion and the Reserv investment, as these are key to future growth.
• Closely watch for Accenture's upcoming fiscal third-quarter results and any adjustments to its fiscal year 2025 growth guidance, particularly in light of Morgan Stanley's expectation of a potential upward revision to the lower end.
• Consider the divergent analyst outlooks, with price targets ranging from $290 to $395, and assess individual risk tolerance before making investment decisions, noting Stifel's Buy rating versus Morgan Stanley's Equalweight.